-+ 0.00%
-+ 0.00%
-+ 0.00%

Junshi Biotech announced the completion of the first patient administration in the phase III clinical trial of JS203 combined chemotherapy for diffuse large B-cell lymphoma.

Zhitongcaijing·10/24/2026 03:41:03
Listen to the news
Junshi Biotech announced the completion of the first patient administration in the phase III clinical trial of JS203 combined chemotherapy for diffuse large B-cell lymphoma.